The other phase I trial tested prophylactic IL-2 activated donor-derived NK cell infusions 60–120 days after matched sibling allo-HCT in 16 patients with hematological diseases (AML, n = 6). This evidence concerns the gene IL2 and acute myeloid leukemia.